TAVAC: comprehensive review of currently available hemostatic products as adjunct to surgical hemostasis.
Hemostasis
Hemostatic agents
Surgeons guide
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
received:
10
03
2024
accepted:
21
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
aheadofprint
Résumé
The use of hemostatic agents by general surgeons during abdominal operations is commonplace as an adjunctive measure to minimize risks of postoperative bleeding and its downstream complications. Proper selection of products can be hampered by marginal understanding of their pharmacokinetics and pharmacodynamics. While a variety of hemostatic agents are currently available on the market, the choice of those products is often confusing for surgeons. This paper aims to summarize and compare the available hemostatic products for each clinical indication and to ultimately better guide surgeons in the selection and proper use of hemostatic agents in daily clinical practice. We utilized PubMed electronic database and published product information from the respective pharmaceutical companies to collect information on the characteristics of the hemostatic products. All commercially available hemostatic agents in the US are described with a description of their mechanism of action, indications, contraindications, circumstances in which they are best utilized, and expected results. Hemostatic products come with many different types and specifications. They are valuable tools to serve as an adjunct to surgical hemostasis. Proper education and knowledge of their characteristics are important for the selection of the right agent and optimal utilization.
Sections du résumé
BACKGROUND
BACKGROUND
The use of hemostatic agents by general surgeons during abdominal operations is commonplace as an adjunctive measure to minimize risks of postoperative bleeding and its downstream complications. Proper selection of products can be hampered by marginal understanding of their pharmacokinetics and pharmacodynamics. While a variety of hemostatic agents are currently available on the market, the choice of those products is often confusing for surgeons. This paper aims to summarize and compare the available hemostatic products for each clinical indication and to ultimately better guide surgeons in the selection and proper use of hemostatic agents in daily clinical practice.
METHODS
METHODS
We utilized PubMed electronic database and published product information from the respective pharmaceutical companies to collect information on the characteristics of the hemostatic products.
RESULTS
RESULTS
All commercially available hemostatic agents in the US are described with a description of their mechanism of action, indications, contraindications, circumstances in which they are best utilized, and expected results.
CONCLUSION
CONCLUSIONS
Hemostatic products come with many different types and specifications. They are valuable tools to serve as an adjunct to surgical hemostasis. Proper education and knowledge of their characteristics are important for the selection of the right agent and optimal utilization.
Identifiants
pubmed: 38630180
doi: 10.1007/s00464-024-10806-x
pii: 10.1007/s00464-024-10806-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ghadimi K, Levy JH, Welsby IJ (2016) Perioperative management of the bleeding patient. Br J Anaesth 117:iii18–iii30. https://doi.org/10.1093/bja/aew358
doi: 10.1093/bja/aew358
pubmed: 27940453
pmcid: 5155545
Price JS, Tackett S, Patel V (2015) Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery. J Med Econ 18(10):777–786. https://doi.org/10.3111/13696998.2015.1046879 . Erratum in: J Med Econ. 2016, 19(3):315–7. PMID: 25934148
Ramirez Manuel G, Castillo George F, Ramirez MA (2019) The economic burden of bleeds and transfusions in selected surgeries: a retrospective multi center analysis from the US perspective. Am J Biomed Sci Res 2(5):211–216. https://doi.org/10.34297/AJBSR.2019.02.000610
doi: 10.34297/AJBSR.2019.02.000610
Hughes MJ, Ventham NT, Harrison EM, Wigmore SJ (2015) Central venous pressure and liver resection: a systematic review and meta-analysis. HPB (Oxford) 17(10):863–871. https://doi.org/10.1111/hpb.12462
doi: 10.1111/hpb.12462
pubmed: 26292655
Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. (2016) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev (10):CD002042. https://doi.org/10.1002/14651858.CD002042.pub4 . Update in: Cochrane Database Syst Rev. 2021, (12):CD002042. PMID: 27731885; PMCID: PMC6457993
Connor JP, Destrampe E, Robbins D, Hess AS, McCarthy D, Maloney J (2023) Pre-operative anemia and peri-operative transfusion are associated with poor oncologic outcomes in cancers of the esophagus: potential impact of patient blood management on cancer outcomes. BMC Cancer 23(1):99. https://doi.org/10.1186/s12885-023-10579-x
doi: 10.1186/s12885-023-10579-x
pubmed: 36709278
pmcid: 9883921
Seong H, Jang Y, Ko E, Lee J, Kim T, Lim CH, Shin HJ, Kim YH, Kim DS (2023) Impact of preoperative red blood cell transfusion on long-term mortality of liver transplantation: a retrospective cohort study. Medicine (Baltimore) 102(37):e34914. https://doi.org/10.1097/MD.0000000000034914
doi: 10.1097/MD.0000000000034914
pubmed: 37713857
Brown KGM, Solomon MJ (2024) Topical haemostatic agents in surgery. Br J Surg 111(1):znad361. https://doi.org/10.1093/bjs/znad361
doi: 10.1093/bjs/znad361
pubmed: 38156466
Tam T, Harkins G, Dykes T, Gockley A, Davies M (2014) Oxidized regenerated cellulose resembling vaginal cuff abscess. JSLS. 18(2):353–356. https://doi.org/10.4293/108680813X13693422518597
doi: 10.4293/108680813X13693422518597
pubmed: 24960506
pmcid: 4035653
Zhou Y, Ma X, Li Z, Wang B (2021) Efficacy, safety, and physicochemical properties of a flowable hemostatic agent made from absorbable gelatin sponge via vacuum pressure steam sterilization. J Biomater Appl 35(7):776–789. https://doi.org/10.1177/0885328220950899
doi: 10.1177/0885328220950899
pubmed: 32838612
Danker Iii W, DeAnglis A, Ferko N, Garcia D, Hogan A (2020) Comparison of fibrin sealants in peripheral vascular surgery: a systematic review and network meta-analysis. Ann Med Surg (Lond) 9(61):161–168. https://doi.org/10.1016/j.amsu.2020.12.003
doi: 10.1016/j.amsu.2020.12.003
Corral M, Ferko N, Hogan A, Hollmann SS, Gangoli G, Jamous N, Batiller J, Kocharian R (2016) A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding. Clinicoecon Outcomes Res 21(8):507–519. https://doi.org/10.2147/CEOR.S112762.PMID:27703386;PMCID:PMC5036832
doi: 10.2147/CEOR.S112762.PMID:27703386;PMCID:PMC5036832
Koea J, Baldwin P, Shen J, et al. (2015) Safety and hemostatic effectiveness of the fibrin pad for severe soft-tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic (non-cardiac) surgery: a randomized, controlled, superiority trial. World J Surg 39(11):2663-9. https://doi.org/10.1007/s00268-015-3106-5 . Erratum in: World J Surg 2015, 39(10):2610. PMID: 26041587
Koea JB, Batiller J, Aguirre N et al (2016) A multicentre, prospective, randomized, controlled trial comparing EVARREST™ fibrin sealant patch to standard of care in controlling bleeding following elective hepatectomy: anatomic versus non-anatomic resection. HPB (Oxford) 18(3):221–228. https://doi.org/10.1016/j.hpb.2015.12.006
doi: 10.1016/j.hpb.2015.12.006
pubmed: 27017161
Assessment of the hemostatic efficacy of PERCLOT, Surgicel Powder, and Arista in a porcine liver abrasion model. December 2021. Baxter Data on File. REF-36820.
Water Mass Absorbance: PERCLOT versus Arista. August 2014. Baxter Data on File. REF-32407.
Evaluation of the adhesive properties of PERCLOT and Arista. September 2022. Baxter Data on File. REF-37550.
Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH (2001) Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233(1):88–96. https://doi.org/10.1097/00000658-200101000-00014
doi: 10.1097/00000658-200101000-00014
pubmed: 11141230
pmcid: 1421171
Lew WK, Weaver FA (2008) Clinical use of topical thrombin as a surgical hemostat. Biologics 2(4):593–599. https://doi.org/10.2147/btt.s2435
doi: 10.2147/btt.s2435
pubmed: 19707440
pmcid: 2727895
Baxter Healthcare. FLOSEAL with RECOTHROM instructions for use.
Baxter Healthcare. Data on File.
Stokes ME et al (2011) Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res 11:135
doi: 10.1186/1472-6963-11-135
pubmed: 21627788
pmcid: 3126703
Baxter Healthcare (n.d.) TISSEEL [fibrin sealant] full prescribing information. http://baxterpi.com/pi-pdf/Tisseel_PI.pdf
Baxter Data on File. REF-27773.
Maisano F, Kjaergård HK, Bauernschmitt R, Pavie A, Rábago G, Laskar M, Marstein JP, Falk V (2009) TachoSil surgical patch versus conventional haemostatic fleece material for control of bleeding in cardiovascular surgery: a randomised controlled trial. Eur J Cardio-Thorac Surg: Off J Eur Assoc Cardio-Thorac Surg 36(4):708–714. https://doi.org/10.1016/j.ejcts.2009.04.057
doi: 10.1016/j.ejcts.2009.04.057
Genyk Y, Kato T, Pomposelli JJ, Wright JK, Sher LS, Tetens V, Chapman WC (2016) Fibrin sealant patch (TachoSil) vs oxidized Regenerated cellulose patch (surgicel original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg 222(3):261–268. https://doi.org/10.1016/j.jamcollsurg.2015.12.007
doi: 10.1016/j.jamcollsurg.2015.12.007
pubmed: 26776356
Baxter Health (n.d.) ARTISS [Fibrin sealant (human)] full prescribing information: http://baxterpi.com/pi-pdf/Artiss_PI.pdf
Spotnitz WD (2014) Fibrin sealant: the only approved hemostat, sealant, and adhesive-a laboratory and clinical perspective. ISRN Surg 4:203943. https://doi.org/10.1155/2014/203943.
doi: 10.1155/2014/203943.
Foster K, Greenhalgh D, Gamelli RL et al (2008) FS 4IU VH S/D clinical study group. Efficacy and safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds: results of a phase 3 clinical study. J Burn Care Res 29(2):293–303. https://doi.org/10.1097/BCR.0b013e31816673f8
doi: 10.1097/BCR.0b013e31816673f8
pubmed: 18354285
HesterShire TRJR, Nguyen DB, Gerut ZE et al (2013) Randomized, controlled, phase 3 study to evaluate the safety and efficacy of fibrin sealant VH S/D 4 s-apr (Artiss) to improve tissue adherence in subjects undergoing rhytidectomy. Aesthet Surg J 33(4):487–496. https://doi.org/10.1177/1090820X13479969
doi: 10.1177/1090820X13479969
Baxter Healthcare Corporation (2009) COSEAL surgical sealant instructions for use. Hayward, CA
Hill A, Estridge TD, Maroney M et al (2001) Treatment of suture line bleeding with a novel synthetic surgical sealant in a canine iliac PTFE graft model. J Biomed 58:308–312
Wallace DG, Cruise GM, Rhee WM et al (2001) A tissue sealant based on reactive multifunctional polyethylene glycol. J Biomed 58:545–555
Natour E, Suedkamp M, Dapunt OE (2012) Assessment on the effect of blood loss and transfusion requirements when adding a polyethylene glycol sealant to the anastomotic closure of aortic procedures: a case-control analysis of 102 patients undergoing Bentall procedures. J Cardiothorac Surg 7:105
doi: 10.1186/1749-8090-7-105
pubmed: 23043723
pmcid: 3477041
Hagberg RC, Safi HJ, Sabik J et al (2004) Improved intraoperative management of anastomotic bleeding during aortic reconstruction: results of a randomized controlled trial. Am Surg 70:307–311
doi: 10.1177/000313480407000408
pubmed: 15098782
Florek H-J, Brunkwall J, Orend K-H, Handley I, Pribble J, Dieck R (2015) Results from a first-in-human trial of a novel vascular sealant. Front Surg 2:29. https://doi.org/10.3389/fsurg.2015.00029
doi: 10.3389/fsurg.2015.00029
pubmed: 26191528
pmcid: 4486749
Stone WM, Cull DL, Money SR (2012) A randomized prospective multicenter trial of a novel vascular sealant. Ann Vasc Surg 26(8):1077–1084
doi: 10.1016/j.avsg.2012.02.013
pubmed: 22939276
Tenaxis Medical, Inc. (2013) Clinical evaluation report for ArterX surgical sealant
Tenaxis Medical, Inc. (2013) Summary of safety and effectiveness: ArterX surgical sealant
Chapman WC, Singla N, Genyk Y et al (2007) A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 205(2):256–265
doi: 10.1016/j.jamcollsurg.2007.03.020
pubmed: 17660072
Bracey A, Shander A, Aronson S et al (2017) The use of topical hemostatic agents in cardiothoracic surgery. Ann Thorac Surg 105:353–360
doi: 10.1016/j.athoracsur.2017.01.096
CryoLife (2001) Summary of safety and effectiveness CryoLife, Inc., BioGlue surgical adhesive. https://www.accessdata.fda.gov/cdrh_docs/pdf/p010003b.pdf . Accessed 15 July 2023
Artivon (n.d.) BioGlue® Surgical Adhesive–Artivion. https://artivion.com/product/bioglue/ . Accessed 15 July 2023
Hoffmann NE, Siddiqui SA, Agarwal S et al (2009) Choice of hemostatic agent influences adhesion formation in a rat cecal adhesion model. J Surg Res 155(1):77–81. https://doi.org/10.1016/j.jss.2008.08.008
doi: 10.1016/j.jss.2008.08.008
pubmed: 19181342
Cziperle DJ (2021) Avitene™ Microfibrillar Collagen Hemostat for adjunctive hemostasis in surgical procedures: a systematic literature review. Med Devices (Auckl) 1(14):155–163. https://doi.org/10.2147/MDER.S298207.PMID:34104007;PMCID:PMC8179802
doi: 10.2147/MDER.S298207.PMID:34104007;PMCID:PMC8179802
Council on Pharmacy and Chemistry (1947) Absorbable gelatin sponge— new and nonofficial remedies. JAMA 135:921
Doria C, Fischer CP, Wood CG, Lifg PM, Marra S, Hart J (2008) Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 24(3):785–794
doi: 10.1185/030079908X273426
pubmed: 18241525
ClinicalTrials.gov (2007) Evaluation of an absorbable surgical hemostatic agent: Thrombi-Gel® versus Gelfoam-thrombin (control). NCT00652314. https://clinicaltrials.gov/ct2/show/NCT00652314 . Accessed 11 Jan, 2023.
Hafer A, Verga J, Sulava E et al (2023) The evaluation of Hemoblast Bellows for arterial hemorrhage control in a swine model of vascular injury. Trauma. https://doi.org/10.1177/14604086231152670
doi: 10.1177/14604086231152670